

## Synthesis, Characterization of Some 1*H*-Tetrazole Derivatives From 3-Aminoacetophene & 3-Amino Phenol

**Zainab Abed-Almuhsein, Athraa Hameed Mekky**

University of Thi-Qar, College of Science, Department of Chemistry, Thi-Qar, 64001, Iraq

**Abstract.** Tetrazole derivatives a-d have been synthesized in this work. The basic tetrazole aab were synthesized by cyclization reaction of primary amine (3-aminoacetophenone, 3-aminophenol ) with sodium azide and triethyl orthoformate in hot glacial acetic acid. The tetrazole linked pyridine -2-one derivatives c were synthesized by the reaction of compound a with aromatic aldehyde (4-bromobenzaldehyde, 4-methoxy- benzaldehyde), ammonium acetate and ethyl cyanoacetate in ethanol absolute. On the other hand, the alkylation reaction of tetrazole derivatives 2 with alkyl chloride (1-chlorobutane, 1, 4-dichloro butane) in the present of potassium carbonate resulted compounds d. The various spectrum techniques that were available, such as FTIR, 1*H*-NMR and 13*C*-NMR spectroscopy, were used to confirm the structures of the produced compounds. Abiological studies were conducted on the prepared compounds 5 and 6 to test their effectiveness against bacteria and as anti-cancer agents. It was found that the compounds d were not possess activity against bacteria. While The cytotoxicity study of b, d against Esophageal cancer cells revealed significant cytotoxic effects with an IC<sub>50</sub> value of 707 µg/mL. The compounds exhibited selective activity, showing a notable difference between its effects on cancerous (SKGT4).

**Keywords:** Tetrazole, pyridine-2-one, 3-amminophenol, Antibacterial activity, Anticancer.

### 1. Introduction

Five-membered heterocyclic compounds with one carbon atom and four nitrogen atoms in the ring are called tetrazoles [1]. In medicinal chemistry, tetrazole scaffolds have garnered significant interest for drug design due to their distinct chemical characteristics, such as metabolic stability, the capacity to function as bio isosteres of carboxylic acids, and favorable acidity (Pka) profiles [2]. Enhancing pharmacokinetic characteristics including solubility, membrane permeability, and binding specificity is a common usage for them. [3] The limits of current chemotherapeutic drugs, including toxicity, side effects, and most importantly, the emergence of resistance, make cancer a significant worldwide concern. [4]. Therefore, One of the main objectives of oncological drug research is the creation of novel cytotoxic agents that can target cancer cells specifically while having the least amount of negative effects on healthy tissue. Tetrazole compounds have become viable options for anticancer treatment in this regard. [5]. Tetrazole-containing drugs can exhibit strong in vitro anti-proliferative or cytotoxic action against a variety of cancer cell lines, according to recent investigations. For instance, one study found that indole-tetrazole derivatives were less hazardous to non-cancerous cells and had IC<sub>50</sub> values in the low micromolar range against breast cancer cell lines (MCF-7, T-47D, and MDA-MB-231) [6]. Similar to this, new tetrazoles containing benzo chromene moieties were created and examined; some of these compounds showed cytotoxicity that was on par with typical drugs like 5-fluorouracil, albeit frequently a little less potent. [7]. The pharmacological effectiveness of tetrazole derivatives against several forms of cancer progression is well recognized[8].

## 2. Experimental.

### 2.1 chemical and Instruments

The Fluka, Sigma-Aldrich, and BLD pharmaceutical companies were the suppliers of all chemicals and solvents. Every chemical was used straight away without further purification. Using solvent systems such ethyl acetate: hexane (4:6), thin layer chromatography (TLC) was used to monitor the development of the chemical reactions. A Perkin Elmer Tensor 27 (Bruker) Fourier-transform infrared (FT-IR) spectrophotometer was used to obtain infrared spectra in the 400–4000  $\text{cm}^{-1}$  spectral region. The specimens were made into discs of potassium bromide (KBr). A Bruker DRX spectrometer running at 500 MHz was used to record both  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectra in order to verify the chemical structures. Tetra methyl silane (TMS) was employed as the internal reference, and deuterated dimethyl sulfoxide ( $\text{DMSO-d}_6$ ) was employed as the solvent. Chemical shifts ( $\delta$ ) are expressed in parts per million, and all NMR measurements were carried out at the University of AL basrah using DMSO as the solvent and TMS as an internal standard.

### 2.2 procedure of Syntheses.

#### 2.2.1 Syntheses tetrazole derivatives a & b.


3- amino acetophenone (2. 703 g, 0. 02 m mole), 3–aminophenol (2. 18 g, 0. 02m mole) respectively was dissolved with glacial acetic acid 50 ml and  $\text{NaN}_3$  (2. 6 g, 0. 02 m mole) and triethyl ortho formate (10 mL, 0. 02 m mole) were included in round bottom flask. For fifty hours, the resultant mixture was heated under reflux. TLC tracked the reaction's development. After completion of the reaction, the reaction mixture pouring the onto crushed ice, the solid was filtere, cleaned with water, and allowed to crystallize again by ethanol [9].

#### 1-(3-(1*H*- tetrazole-1-yl) phenyl) ethan-1-one (a).

The compound was obtained as pale-brown crystals with a yield of 66%, MP. 166–168°C, Rf= (0. 61): IR ( $\nu \text{ cm}^{-1}$ ) : 3107(C-H of Tetrazole ring), 3061 (C-H Ar. ), 1682 (C=O Ketone), 1606 (C=N).  $^1\text{H}$ -NMR(DMSO- $\text{d}_6$ ) :10. 20 (s, 1H, HC=N tetrazole), 8. 39 -7. 78 aromatic proton), 2. 66 (s, 3H,  $\text{CH}_3$ ).  $^{13}\text{C}$ - NMR (101MHz, DMSO- $\text{d}_6$ :  $\delta$  ppm) : 196 (C=O), 142 (C =N of tetrazole), 138-120 (Aromatic Carbon), 26 (carbon of  $\text{CH}_3$ ).


#### 3 -(1*H*-tetrazol-1-yl) phenol (b).

The compound was obtained as brown crystals with a yield of 81%, MP. 166 –168°C, Rf= (0. 5) ; IR ( $\nu \text{ cm}^{-1}$ ) : 3156 (O -H), 3111 (C-H of Tetrazole ring), 3065 (C-H Ar. ), 1606 (C=N),  $^1\text{H}$ -NMR (DMSO- $\text{d}_6$ ) :10. 04 (O- H), 10. 20 (s, 1H, HC=N tetrazole), 7. 43-6. 93 (dd, 4H, aromatic proton).  $^{13}\text{C}$ - NMR (101MHz, DMSO- $\text{d}_6$ :  $\delta$  ppm) :158 (C-OH), 142 (C=N of tetrazole), 134-107 (aromatic Carbon). [10]



#### 2. 2. 2 General procedure for preparation (c).

A mixture of 1-(4-(1*H*- tetrazole-1-yl) phenyl) ethan-1-one (a) (0. 56 gm, 3mmole), ethyl cyanoacetate (0. 319 mL, 3mmole), ammonium acetate (0. 231g, 3mmole) with appropriate aldehyde (4- bromobenzaldehyde, 4- ethoxy benzl aldehyde) 3mmole respectively, in 35mL of ethanol in round bottom flask. The completion of reaction was monitor by TLC. The reaction mixture was heated under reflux. The end point of the reaction was monitor by TLC. Then, the resulted precipitate was filtered, dried and recrystallized from ethanol to obtain the desired chemicals.



### 6-(3-(1H-tetrazol-1-yl) phenyl) -4-(4-bromophenyl) -2-oxo-1, 2-dihydro- pyridine-3-carbonitrile (1c).


light yellow; m. p 177-179 °C, Yield (55 %);  $R_f$  = 0. 32 (hexan: ethyl acetet 6:4); IR (KBr) ( $\text{cm}^{-1}$ ): 3275 (NH), 3143(C-H of tetrazole), 3066, 3008 (C-H of Ar.), 2222( $\text{C}\equiv\text{N}$ ), 1732 (C=O amide), 1685 ( $\text{C}=\text{N}$ ), 968 (C-H out of plane),  $^1\text{H}$ -NMR (400 MHz, DMSO- $d_6$ :  $\delta$  ppm): 13. 02(s, 1H, NH), 10. 15(s, 1H, CH=N of tetrazole), 8. 48 -7. 73(m, H, aromatic proton), 7. 13 (s, 1H, pyridone (C-H)).  $^{13}\text{C}$ -NMR (101MHz, DMSO- $d_6$ :  $\delta$  ppm), 162 (C=O of pyridine -2-one), 128(C-H) Pyridonering, 142( $\text{C}=\text{N}$  of tetrazole), 116 ( $\text{C}\equiv\text{N}$ ), 135, 134, 131, 130, 124, 123, 120 (Carbon of Phenyl ring).

### 6-(3-(1H-tetrazol-1-yl) phenyl) -4-(4-ethoxyphenyl) -2-oxo-1, 2-dihydropyridine-3-carbonitrile (2c)

Black powder, Yield (73 %);  $R_f$  = 0. 4 (hexan: ethyl acetet 6:4); M. p 193-195 °C; IR (KBr) ( $\text{cm}^{-1}$ ): 3116 (NH), 3062 (C-H of tetrazole), 2016 (C-H of Ar.), 2214 ( $\text{C}\equiv\text{N}$ ), 1651 (C=O) amide), 1581 ( $\text{C}=\text{N}$ ), 995 (C-H out of plane).  $^1\text{H}$ - NMR (400 MHz, DMSO- $d_6$ :  $\delta$  ppm): 12. 82 (s, 1H, NH), 10. 15 (s, 1H, CH=N tetrazole) 8. 47 (s, 1H, aromatic proton), 8. 10 (s, 3H, aromatic proton), 7. 12 (s, 1H, pyridone (C-H), 4. 13(q, 2H,  $\text{OCH}_2$ ), 1. 38(s, 3H,  $\text{CH}_3$ )  $^{13}\text{C}$ -NMR (101MHz, DMSO- $d_6$ :  $\delta$ ppm), 160 (C=O), 142( $\text{C}=\text{N}$  of tetrazole), 134, 130, 128, 127, 123, 120, 114, 113, 112(aromatic carbons), 116 ( $\text{C}\equiv\text{N}$ ), 63( $\text{O}-\text{CH}_2$ ), 14( $\text{CH}_3$ ).

### 2.2.3 General procedure for preparation tetrazole derivatives (d).

A mixture of 4-(1H-tetrazol-1-yl) phenol 2 (0. 81 g, 5mmole), Potassium carbonate (0. 69 g, 5mmole), 1-chloro butane, 1, 4-dichlorobutane (10 ml, 10mmole) respectively, in (50 ml) of acetone in round bottom flask. Then, the resultant mixture was heated under refluxed. TLC was used to monitor the reaction. Next, the reaction mixture was cooled to room temperature and poured in cold water, then 50ml of chloroform was added, then separated the organic layer using a separating funnel, dried and evaporated the solvent desired chemicals.



### 1-(3-butoxyphenyl) -1H-tetrazole (1d).

Pale yellow; mp 75-77 °C, Yield (63 %);  $R_f$  = 0. 63 (hexan: ethyl acetet 6:4); IR (KBr) ( $\text{cm}^{-1}$ ): 3143(C-H of tetrazole), 3097 (C-H of Ar.), 2954- 2870 (C-H alphatic), 1203 (C-O), 1597 ( $\text{C}=\text{N}$ ), 972 (C-H bending of  $\text{CH}_3$ ),  $^1\text{H}$ - NMR (400 MHz, DMSO- $d_6$ :  $\delta$  ppm): 10. 11(s, 1H, CH=N tetrazole), 7. 56-7. 46 (m, H, aromatic proton) 4. 07 (t, 2H,  $\text{O}-\text{CH}_2$ ), 1. 73(m, 2H,  $\text{CH}_2-\text{CH}_2-\text{CH}_3$ ), 1. 46 (m, 2H,  $\text{CH}_2-\text{CH}_3$ ), 0. 94 (s, 3H,  $\text{CH}_3$ ):  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$ ),  $\delta$ (ppm) :159 (C-O), 142 ( $\text{C}=\text{N}$  of tetrazole), 134, 131, 115, 112, 107 (aromatic carbons), 67( $\text{O}-\text{CH}_2$ ), 30 ( $\text{O}-\text{CH}_2-\text{CH}_2$ ), 18( $\text{CH}_2-\text{CH}_3$ ), 13 ( $\text{CH}_3$ ).

### 1-(3-(3-chloropropoxy) phenyl) -1H-tetrazole (2d).

Pale white, Yield (77 %); M. p =84-86 °C,  $R_f$  = 0. 28 (hexan: ethylacetet 6:4); IR (KBr) ( $\text{cm}^{-1}$ ): 3140(C-H of tetrazole), 3078 (C-H of Ar.) 2954-2877 (C-H, alphatic protons), 1195 (C-O), 1504 ( $\text{C}=\text{N}$ ), 1396 (C-H bending of  $\text{CH}_3$ ).  $^1\text{H}$ - NMR (400 MHz, DMSO- $d_6$ :  $\delta$  ppm): 10. 11(s, 1H, CH=N tetrazole), 7. 57-7. 13 (m, H, aromatic proton), 4. 17(t, 2H,  $\text{O}-\text{CH}_2$ ), 3. 73 (t, 2H,  $\text{CH}_2-\text{Cl}$ ), 1. 95(m,

2H, CH<sub>2</sub>-CH<sub>2</sub>), 1.88(m, 2H, CH<sub>2</sub>-CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>), δ(ppm): 159 (C-O), 142 (C-H of tetrazole), 107-134 (aromatic carbons), 67 (O-CH<sub>2</sub>), 45(-CH<sub>2</sub>-Cl), 28(CH<sub>2</sub>-CH<sub>2</sub>), 25 (CH<sub>2</sub>-CH<sub>2</sub>).


## 2.3 Biological activity study. [11]

### 2.3.1 -Antibacterial activity of compounds 5 and 6.

In this investigation, two different kinds of harmful bacteria used *Escherichia coli*, which is Gram-negative, and *Staphylococcus aureus*, which is Gram-positive. substances that have therapeutic use. Chemical solutions of tetrazole derivatives 5, 6 were produced in concentrations of 500 and 1000 mg/ml using the solvent Dimethyl Sulfoxide DMSO in order to quantify and ascertain the minimum inhibitory concentration [12]. The bacterial isolates' sensitivity test was performed by diffusion method in Mueller-Hinton agar, a transparent food medium that is helpful in figuring at how sensitive microbes are to antibiotics due to the fact that it includes casein and extracted starch [13]. The majority of bacteria and microorganisms can grow in it [14]

After the medium was created and autoclave sterilized, it was divided into plates and allowed to solidify. three tiny pits were then made in each plate [15] After that, it was kept in a for 24 hours at 37°C. The diameter of the inhibition visible in the dishes surrounding the holes utilized determines the derivatives activity derivatives employed, since the findings were read the following day [16].


When compared to the diameter of inhibition for antibiotics, inhibition refers to the rise in the biological activity of the produced drugs [17]. Where the laboratory results. for compounds 5 and 6 proved that they do not possess antibacterial activity, meaning their inability to inhibit bacterial activity at these concentrations [18]. Figure (1).



**Figure (1): Antibacterial activity compounds 5, 6 against *Escherichia coli* and *Staphylococcus aureus***

### 2.3.2 Cytotoxic of compounds b, 1d and 2d.

The cytotoxic effect of the compounds b, 1d and 1d were evaluated on the human esophageal cancer cell line SKGT-4 using the MTT assay at a wavelength of 620 nm. Cells were exposed to concentrations of 0, 500, and 1000 µg/mL, with four technical replicates for each concentration. As shown in Figure (2).



**Figure 2: Cytotoxicity Assay for b, 1d, 2d Compound on SKGT-4 cell.**

### 3- Results and discussion.

#### 3.1 Synthesis and Characterization.

Cyclization reaction of primary amine with sodium azide and ethyl orthoformate was used to synthesize tetrazole derivatives 1 and 2. The structures of synthesized compounds have been established by spectrum analysis (FT-IR, NMR). FT-IR spectra showed disappearance of absorption bands of stretching of  $\text{NH}_2$  and appearance of a new absorption band of stretching of C-H of tetrazole at  $3107, 3111 \text{ cm}^{-1}$  respectively. The  $^1\text{H}$ NMR spectra exhibited singlet signals at 10, 20, 10, 20 ppm because of the proton of  $\text{CH}=\text{N}$  in the synthesized tetrazole ring. On the other hand,  $^{13}\text{C}$ NMR



displayed signal at 142, 142 ppm respectively, refer to carbon of C=N. The tetrazole derivatives linked pyridine-2-one were synthesized from the cyclization reaction of tetrazole derivative 1 with aromatic aldehyde and ethylcyanoacetate in the presence of ammonium acetate to produce compounds 3 and 4. The structure of preparing derivatives have been established by spectra data. The FT-IR showed the departure absorption band of carbonyl group at 1732, 1651  $\text{cm}^{-1}$  and appearance new bands at 3275, 3116  $\text{cm}^{-1}$  of stretching vibration of NH, while bands at 2222, 2214  $\text{cm}^{-1}$  of stretching vibration of CN. The  $^1\text{H}$ -NMR spectra showed singlet signal at 13.02, 12.82 ppm refer to protons NH in the pyridine-2-one ring. Alternatively, the spectra showed signals at 7.13, 7.12 ppm due to protons of pyridine (C-H). On the other hand the  $^{13}\text{C}$ -NMR exhibited signals at 162, 160 ppm refer to C=O of the pyridine-2-one ring, signals at 116, 116 due to carbon of CN.

The alkylation reaction of hydroxyl group in the tetrazole derived 2 with alkyl halide in the presence of  $\text{K}_2\text{CO}_3$  as catalyst produce tetrazole derivatives 5 and 6, the structures of synthesized derivatives exhibited by spectra data. The FT-IR spectrum demonstrated disappearance absorption band at 3156  $\text{cm}^{-1}$  which caused by stretching of OH group and appearance new absorption bands at 2954-2870, 2954-2877  $\text{cm}^{-1}$  of stretching vibration of C-H aliphatic.  $^1\text{H}$ NMR spectrum for compound 5 showed a new signals at 4.07, 1.73-1.46, 0.94 ppm refer to aliphatic protons of  $\text{CH}_2$  and  $\text{CH}_3$  groups. A new signals at 30, 18.13 ppm have been showed in the  $^{13}\text{C}$ -NMR. Oppositely, the  $^1\text{H}$ NMR of compound 6 showed a new signals at 4.17(t, 2H, O- $\text{CH}_2$ ), 3.35(t, 2H,  $\text{CH}_2\text{-Cl}$ ), 1.95(t, 2H,  $\text{CH}_2\text{-CH}_2$ ), 1.87(m, 2H,  $\text{CH}_2\text{-CH}_2$ ), 1396(C-H bending of  $\text{CH}_3$ ). Despite the fact that,  $^{13}\text{C}$ NMR displayed a new signals at 67ppm (O- $\text{CH}_2$ ), 45ppm ( $\text{CH}_2\text{-Cl}$ ), 28ppm ( $\text{CH}_2\text{-CH}_2$ ), 29ppm( $\text{CH}_2\text{-CH}_2$ ).

### 3.2 Biological Activity

#### 3.2.1 Antibacterial Activity

Most of synthesized tetrazole derivatives 5, 6 were tested against bacteria (*Escherichia coli*, *Staphylococcus aureus*). As the results of the bioactivity test for compounds 5 and 6 showed no inhibitory effect at concentrations of 500 and 1000 micrograms/ml against the bacterial strains E. coli (Gram-negative) and Stph. aureus (Gram-positive).

#### 2.3.2: Anticancer Activity [19, 20].

The cytotoxic activity of the compounds b, 1d and 2d was evaluated against the human esophageal cancer cell line SKGT-4 using the MTT assay at 620 nm. At the control (0  $\mu\text{g/mL}$ ), the mean absorbance of compound 2 was 0.462, the mean absorbance was 0.467, with negligible inhibition (1.07%). At 500  $\mu\text{g/mL}$ , the mean absorbance decreased to 0.332, with an inhibition ratio of 28.8% (SD  $\pm 1.53$ ). while at 1000  $\mu\text{g/mL}$ , the mean absorbance was 0.334, with a similar inhibition ratio of 28.4% (SD  $\pm 4.62$ ). The results indicate that the compound produced only a modest cytotoxic effect on SKGT-4 cells, reaching inhibition levels below 30% even at the highest tested concentration. Due to the plateau in response and absence of a clear dose-response trend beyond 500  $\mu\text{g/mL}$ , it was not possible to determine a reliable  $\text{IC}_{50}$  value within the tested concentration range (Figure 2). The mean absorbance of compound 5 was 0.462, with a negligible inhibition rate of approximately 1.1%. At 500  $\mu\text{g/mL}$ , the mean absorbance dropped significantly to 0.101, corresponding to a strong inhibition rate of approximately 78.5% (SD  $\pm 1.68$ ). At 1000  $\mu\text{g/mL}$ , the absorbance further decreased to 0.076, with inhibition increasing slightly to 83.8% (SD  $\pm 0.44$ ). Curve fitting analysis revealed an  $\text{IC}_{50}$  707.1  $\mu\text{g/mL}$  (Log  $\text{IC}_{50}$  = 2.849), with a steep Hill Slope of 41.1 and a correlation coefficient ( $R^2$  = 0.861), confirming a sharp dose-response transition and a relatively strong inhibitory effect at higher concentrations. The results indicate that the m3 compound exerts a pronounced cytotoxic effect on SKGT-4 cells at higher concentrations. Both 500  $\mu\text{g/mL}$  and 1000  $\mu\text{g/mL}$  produced strong inhibition rates of 78.5% and 83.8%, respectively, suggesting that the compound reaches its cytotoxic plateau starting from 500  $\mu\text{g/mL}$ . This highlights the potent inhibitory capacity of the compound at elevated doses, while also confirming that increasing the concentration beyond 500  $\mu\text{g/mL}$  does not markedly enhance cytotoxicity, indicating a saturation effect. The mean absorbance of compound 6 was 0.462, with negligible inhibition. (%1.1)At 500  $\mu\text{g/mL}$ , absorbance markedly decreased to 0.074, corresponding to a sharp increase in inhibition (% 84.2)At 1000  $\mu\text{g/mL}$ , the absorbance remained low (0.074), with inhibition persisting at 84.2%, indicating that the plateau of cytotoxic activity was reached at 500  $\mu\text{g/mL}$ .

The curve-fitting analysis showed a  $\text{LogIC}_{50} = 2.849$ , corresponding to an  $\text{IC}_{50} 707 \mu\text{g/mL}$ , with a steep Hill Slope = 41.1, indicating a sharp transition between inactive and highly active concentrations. The absence of an  $R^2$  value suggests limitations in regression accuracy, but the data strongly demonstrate that compound m4 exerts a potent cytotoxic effect once the effective dose threshold is reached.

#### 4. Conclusion

In order to obtain new compounds with promising chemical and biological potentials, a group of tetrazole derivatives were successfully generated and described using meticulously explored synthetic pathways at the end of this research. The results of the spectroscopic analysis, which included infrared spectra (FT-IR), proton nuclear magnetic resonance ( $^1\text{H}$ -NMR), and possibly carbon ( $^{13}\text{C}$ -NMR) spectra, along with other supporting techniques, demonstrated a clear match with the suggested structures of the prepared compounds, confirming the accuracy of the final chemical structures and the success of the preparation steps.

Additionally, the study demonstrated that the addition of the tetrazole group to the organic structure enhances the chemical activity of the resultant compounds and gives them comparatively stable physical properties, making them potential candidates for use in applied chemistry or pharmaceuticals.

For the purpose to create more potent and selective compounds in the future, this study suggests investigating the Structure Activity Relationship and carrying out additional research to assess the biological characteristics of these derivatives, especially in the areas of antibacterial and anti-inflammatory agents.

#### References.

1. Dalal, M. J. and Mekky, A. H., 2022. Synthesis, Characterization and Antioxidant Evaluation of Some Tetrazole Derivatives. *Indonesian Journal of chemistry*, 22(6), pp. 1596-1604.
2. Rathore, G. and Bhattacharya, A., 2025. Comprehensive In Silico Exploration of Some Novel Tetrazole Molecules. *Int J Med Phar Sci| Vol*, 15(01), p. 8.
3. El-Sewedy, A., El-Bordany, E. A., Mahmoud, N. F., Ali, K. A. and Ramadan, S. K., 2023. One-pot synthesis, computational chemical study, molecular docking, biological study, and in silico prediction ADME/pharmacokinetics properties of 5-substituted 1 H-tetrazole derivatives. *Scientific Reports*, 13(1), p. 17869.
4. Nayak, S. G., Das, V. B., Kamat, V. and KD, V., 2025. Advances in the development of potent heterocyclic anticancer agents: a critical review. *Synthetic Communications*, pp. 1-27.
5. Olejarz, W., Sadowski, K., Roszkowski, P., Bielenica, A., Wiśniewski, M., Struga, M. and Szulczyk, D., 2025. Design and in vitro evaluation of novel tetrazole derivatives of dianisidine as anticancer agents targeting Bcl-2 apoptosis regulator. *Scientific Reports*, 15(1), p. 17634.
6. Kaur, K., Verma, H., Gangwar, P., Dhiman, M. and Jaitak, V., 2024. Design, synthesis, in vitro and in silico evaluation of indole-based tetrazole derivatives as putative anti-breast cancer agents. *RSC Medicinal Chemistry*, 15(4), pp. 1329-1347.
7. Gorle, S., Maddila, S., N Maddila, S., Naicker, K., Singh, M., Singh, P. and B Jonnalagadda, S., 2017. Synthesis, molecular docking study and in vitro anticancer activity of tetrazole linked benzochromene derivatives. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, 17(3), pp. 464-470.
8. Prabhu, D. J., John, F., Steephani, M., John, J., Sreehari, A. P. and Chandrika, B. B., 2024. Multicomponent reactions for the synthesis of tetrazole derivatives: Discovery and validation of a novel anticancer agent active against ER positive cancers. *Results*
9. Mekky, A. H., Jaber Dalal, M., G. Sager, A., Salmn, N. A. A., Abbas Talib Abd Ali, & Jayapal, M. (2023). Synthesis, characterization and Theoretical study of some 2-Oxopyridine Carbonitrile

- derivatives that contain tetrazole ring and evaluation of their Biological activity. *University of Thi-Qar Journal of Science*, 10(2), 235-241. <https://doi.org/10.32792/utq/utjsci/v10i2.1145>
10. Al alawy, H., & Ibrahim A. Flifel. (2023). Synthesis, Characterization and Anticancer Study of New 3-[(2Z)-2-(2-hydroxybenzylidene) hydrazinyl]-5-(2-hydroxyphenyl)-1, 3, 4-oxadiazol-3-ium and its Transition Metal Complexes *University of Thi-Qar Journal of Science*, 10(2), 98-<https://doi.org/10.32792/utq/utjsci/v10i2.1094>
  11. Thejeel E, Mekky AH. Synthesis, Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET) and molecular docking studies of some pyridin-2 (1H) -one derived from a Apocynin in Thi-Qar Governorate. *University of Thi-Qar Journal of Science*. 2023 Dec 23;10(2) :73-80. DOI: <https://doi.org/10.32792/utq/utjsci/v10i2.1089>
  12. M. A. Gouda, M. Al-Ghorbani,, M. H Helal,, A. Salem, M. A. & E. H. A. Hanashalshahaby,. "A review: Recent progress on the synthetic routes to 1(5) -substituted 1H-Tetrazoles and its analogs". *Synthetic Communications Reviews*. Vol 50, P. P. 1–27, 2020.
  13. Shannak, Q. A. and Hebeb, H. R., 2020. Characteristic Studying and Biological Effect of Synthesized Complexes Pd (II) and Hg (II) with Uracil dithiocarbamate and Phosphine's. *Systematic Reviews in Pharmacy*, 11(3).
  14. Shannak, Q. A., Najim, T. M. and Madab, D. I., 2022. Evaluation of the level of vitamin D3 in the blood serum of patients infected with COVID-19 in Al-Amiriya city. *Technium BioChemMed*, 3(2), pp. 127-135.
  15. Posten, C. H. and Cooney, C. L., 1993. Growth of microorganisms. *Biotechnology*, 1, pp. 111-162.
  16. Rajeswari, M., Nagaraju, B., Balaji, H., Ali, S., Balaji, M., Karunakar, P., Venkata Rao, C. and Maddila, S., 2025. Design, Synthesis, Biological Activity, Molecular Docking and Dynamic Studies of Novel Benzimidazole-Integrated 1, 2, 3, 4-Tetrazole
  17. A. H. Dalaf and F. H. Jumaa, "Synthesis, characterization of some 1, 3-oxazepane-4, 7-dione by traditional and microwave routes method and evaluation of their biological activity, " *Al-Utroha for Pure Science*, vol. 8, pp. 93-108, 2018. Derivatives. *Chemistry & Biodiversity*, p. e202500353.
  18. Ngurah, B. I. G. M. and Widinugraheni, S., 2025. Synthesis, Characterisation of C-Methoxy Phenyl Calix [4] resorcinaryl Octacinnamate and Their Antibacterial Activity. *Journal of Scientific Research*, 17(3), pp. 901-909.
  19. Al-Ali, A. A., Alsalami, K. A. and Athbi, A. M., 2022. Cytotoxic effects of CeO2 NPs and  $\beta$ -Carotene and their ability to induce apoptosis in human breast normal and cancer cell lines. *Iraqi Journal of Science*, pp. 923-937.
  20. Falih, S. M., Al-Saray, S. T., Alfariis, A. A. and Al-Ali, A. A., 2022. The synergistic effect of eucalyptus oil and retinoic acid on human esophagus cancer cell line SK-GT 4. *Egyptian journal of medical human genetics*, 23(1), p. 70.